Document Classification

Section Type: RESULTS

Text: During a median follow-up of 18 months (interquartile range 12-27 months), mean within-group eGFR change from baseline was +0. 14 mL/min/1. 73 m for TDF, -0. 22 mL/min/1. 73 m for FTC-TDF, and +1. 37 mL/min/1. 73 m for placebo, translating into average declines in eGFR attributable to PrEP vs placebo of -1. 23 mL/min/1. 73 m (95 % CI, -2. 06 to -0. 40 ; P =. 004) for TDF and -1. 59 mL/min/1. 73 m (95 % CI, -2. 44 to -0. 74 ; P <. 001) for FTC-TDF.